Cytotoxicity and DNA damage caused by 4-demethoxydaunorubicin and its metabolite 4-demethoxy-13-hydroxydaunorubicin in human acute myeloid leukemia cells

[1]  M. Zucchetti,et al.  Pharmacokinetics of 4-demethoxydaunorubicin in cancer patients , 2004, Cancer Chemotherapy and Pharmacology.

[2]  M. D’Incalci,et al.  Comparison of intracellular drug retention, DNA damage and cytotoxicity of derivatives of doxorubicin and daunorubicin in a human colon adenocarcinoma cell line (LoVo). , 1989, Biochemical pharmacology.

[3]  R. Herrmann,et al.  Oral idarubicin as single-agent treatment of acute nonlymphocytic leukemia in poor-risk patients. , 1987, Cancer treatment reports.

[4]  J. Reiffers,et al.  Idarubicin in the treatment of relapsed or refractory acute myeloid leukemia. , 1987, Cancer treatment reports.

[5]  M. Carli,et al.  Phase II study of idarubicin administered i.v. to pediatric patients with acute lymphoblastic leukemia. , 1987, Cancer treatment reports.

[6]  C. Haanen,et al.  Plasma and human leukemic cell pharmacokinetics of oral and intravenous 4‐demethoxydaunomycin , 1986, Clinical pharmacology and therapeutics.

[7]  J. Griffin,et al.  Clonogenic cells in acute myeloblastic leukemia. , 1986, Blood.

[8]  F. Zunino,et al.  Single-strand DNA breaks induced by chromophore-modified anthracyclines in P388 leukemia cells. , 1986, Cancer research.

[9]  F. Arcamone,et al.  Synthesis and antitumor activity of 4-demethoxydaunorubicin, 4-demethoxy-7,9-diepidaunorubicin, and their beta anomers. , 1976, Cancer treatment reports.

[10]  B. Pike,et al.  Human bone marrow colony growth in agar‐gel , 1970, Journal of cellular physiology.